Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
Titel:
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial
Auteur:
Élez, E. Kocáková, I. Höhler, T. Martens, U.M. Bokemeyer, C. Van Cutsem, E. Melichar, B. Smakal, M. Csőszi, T. Topuzov, E. Orlova, R. Tjulandin, S. Rivera, F. Straub, J. Bruns, R. Quaratino, S. Tabernero, J.